Oncology prior authorization at Aetna
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Aetna oncology PA at a glance
Aetna reviews oncology PA submissions against its medical policy library, with rules drawn primarily from NCCN Clinical Practice Guidelines in Oncology + NCCN Drugs & Biologics Compendium. Aetna-specific context: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
Documentation packet — what to send
- Histologic diagnosis with ICD-10-CM code
- Stage at diagnosis + current line of therapy
- Biomarker test result with date and lab
- Prior systemic therapies tried, response, and reason for discontinuation
- Performance status (ECOG or KPS)
- NCCN-supported indication with version number
Common denial patterns to pre-empt
Patterns observed in oncology across payers, and where Aetna's book of business overlaps:
- Off-label use not in FDA label
- Step therapy on biosimilar before reference biologic
- Site-of-care reduction (home infusion vs hospital)
- Frequency or duration outside policy
- Companion diagnostic not documented (HER2, PD-L1, MSI, BRCA, etc.)
- Step therapy on specialty drugs
- Out-of-network ER reduction
Appeal angles when Aetna denies
- NCCN Compendium Category 1/2A citation for off-label support
- Pivotal trial citation by name with FDA approval date
- Genomic biomarker documentation (FoundationOne, Guardant360, MSK-IMPACT)
- Tumor board recommendation
Peer-to-peer prep
- Have the NCCN page reference open on screen (version + page #)
- Open the patient's biomarker report alongside the chart
- Lead with the FDA-approved indication; pivot to NCCN if at the edge of the label
- State the line of therapy explicitly (1L, 2L, 3L) — common point of P2P misunderstanding
Drug-specific PA criteria at Aetna
Deep dives on each drug's PA criteria at Aetna:
Frequently asked questions
What documentation does Aetna need for oncology prior authorizations?
Aetna's PA packet for oncology typically includes: Histologic diagnosis with ICD-10-CM code; Stage at diagnosis + current line of therapy; Biomarker test result with date and lab; Prior systemic therapies tried, response, and reason for discontinuation. NCCN Clinical Practice Guidelines in Oncology + NCCN Drugs & Biologics Compendium citations strengthen the submission.
What's the turnaround at Aetna?
Aetna standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which oncology drugs does Aetna most often PA-restrict?
Top targets in oncology: pembrolizumab, rituximab, trastuzumab, bevacizumab, nivolumab. Each follows the per-drug step therapy + documentation requirements published in Aetna's medical policy library.
How do I prep a peer-to-peer with Aetna in oncology?
Have the NCCN page reference open on screen (version + page #) Open the patient's biomarker report alongside the chart Have the policy URL and the patient's chart open before the call.
Generate a Oncology PA packet
Open ApprovalHelp — generate a oncology PA packet tailored to Aetna's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com